Non-conventional and investigational PET radiotracers for breast cancer: a systematic review
M Balma, V Liberini, M Racca, R Laudicella… - Frontiers in …, 2022 - frontiersin.org
Breast cancer is one of the most common malignancies in women, with high morbidity and
mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine …
mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine …
Effect of aerobic exercise on cardiotoxic outcomes in women with breast cancer undergoing anthracycline or trastuzumab treatment: a systematic review and meta …
Z Ma, S Yao, Y Shi, N Lu, F Cheng - Supportive Care in Cancer, 2022 - Springer
Purpose We aimed to assess the impact of aerobic exercise (AE) on parameters related to
cardiotoxicity in breast cancer (BC) patients receiving anthracycline or trastuzumab …
cardiotoxicity in breast cancer (BC) patients receiving anthracycline or trastuzumab …
Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer
F Shao, Z Pan, Y Long, Z Zhu, K Wang, H Ji… - Journal of …, 2022 - Springer
Background Triple-negative breast cancer (TNBC) is more prone to distant metastasis and
visceral recurrence in comparison to other breast cancer subtypes, and is related to dismal …
visceral recurrence in comparison to other breast cancer subtypes, and is related to dismal …
Homodimer 99mTc-HYNIC-E(SSSLTVPWY)2 peptide improved HER2-overexpressed tumor targeting and imaging
We hypothesized that a novel design of the LTVPWY (LY) peptide might exhibit a great
potential for improving binding affinity and targeting HER2-overexpressed tumors. Hence …
potential for improving binding affinity and targeting HER2-overexpressed tumors. Hence …
[PDF][PDF] Molecular imaging for estrogen receptor-positive breast cancer: clinical applications of whole body and dedicated breast positron emission tomography
K Goodman, MK Abel, C Lawhn-Heath… - Surgical oncology clinics …, 2022 - Elsevier
Summary Recently FDA-approved, 18 F-FES is a well-studied radiopharmaceutical with the
ability to provide molecular imaging of ER-positive breast cancer. In the setting of whole …
ability to provide molecular imaging of ER-positive breast cancer. In the setting of whole …
[HTML][HTML] Evaluation of a novel EphA2 targeting peptide for triple negative breast cancer based on radionuclide molecular imaging
B Qu, Y Han, T Liang, C Zhang, G Hou, F Gao - Arabian Journal of …, 2022 - Elsevier
A new strategy for the early diagnosis of triple-negative breast cancer (TNBC) is urgently
needed however specific targets are lacking. EphA2 has been reported to be over …
needed however specific targets are lacking. EphA2 has been reported to be over …